JPMorgan downgraded Pliant Therapeutics (PLRX) to Neutral from Overweight without a price target after the company announced a voluntary pause ...
In a report released on February 7, Glenn Schorr from Evercore ISI maintained a Buy rating on Blue Owl Capital (OWL – Research Report), with a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback